NCT04241601View on ClinicalTrials.gov

Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 5, 2020

Primary Completion Date

January 25, 2023

Study Completion Date

January 25, 2023

Conditions
Acute Coronary Syndromes
Interventions
DRUG

Interleukin-2 [IL-2]

Active Comparator: IL-2 plays a key role in Treg cell development, expansion, survival and suppressive function

OTHER

Placebo Dextrose 5% solution

Placebo Comparator: Dextrose 5% solution

Trial Locations (1)

CB20QQ

Addenbrooke's Hospital, Cambridge

All Listed Sponsors
lead

Cambridge University Hospitals NHS Foundation Trust

OTHER

NCT04241601 - Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY | Biotech Hunter | Biotech Hunter